TX-FLUENCE
Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, today released its RAZR Modular System, the company’s newest LED solution for vertical farmers featuring market-leading efficacies of 2.6 µmol/J under Fluence’s PhysioSpec™ BROAD R3 white spectrum.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210615005453/en/
Fluence’s years of experience collaborating with vertical farmers have proven PhysioSpec™ BROAD R3 is the optimal spectrum choice for crop propagation and full-cycle cultivation for a multitude of leafy greens, microgreens, herbs and other vegetables. Under Fluence’s BROAD R3 spectrum, the newest RAZR system is 18% more efficient than previous generations. The RAZR Modular System’s mechanical mounting and electrical wiring are also highly configurable and easily integrate into various racking styles. The system’s flexible design makes it uniquely suited for scale in a vertical farming environment.
“Vertical farmers are fueling some of the greatest innovations in modern crop production,” said David Cohen, CEO of Fluence. “By simplifying the food supply chain, vertical farms can deliver fresh, nutritional produce to localized regions. These intricate cultivation facilities typically require custom, multilayer racking systems with specialized LED lighting solutions that can optimize plant development through various growth stages. Our RAZR Modular System not only reduces overall operational expenses through its efficient and configurable fixtures, but also offers a proven spectrum for propagation and vertical cultivation for leafy greens, microgreens, herbs and other vegetables.”
Fluence distributes its RAZR Modular System to vertical farmers directly and through partners such as Ecopromt, a leading greenhouse consultancy. Ecopromt’s cultivation experts have designed a fully integrated cart system featuring the RAZR Modular System as well as a proprietary irrigation system. Ecopromt’s integrated cart system has been installed in multiple vertical farms throughout Europe and the U.S.
“Our team has been designing, developing and growing under the most advanced cart systems for vertical farming for nearly a decade,” said Tom Jönsson, head of sales for Ecopromt. “Ecopromt’s fully integrated system is easy to install and built to scale as a vertical farm grows. Combined with our irrigation system and configurable design, RAZR’s modular capabilities provide homogenous light distribution across crops, enabling growers to produce consistent, high-quality plants under some of the industry’s most efficient lighting technology.”
Based in Brooklyn, New York, aquaponic vertical farm Upward Farms leverages Fluence’s RAZR Modular System to optimize growth cycles for several microgreen and baby green variants through different stages of cultivation.
“The RAZR system is flexible, efficient and powerful, which allowed us to quickly and seamlessly integrate it into our grow stacks,” said Ben Silverman, CTO of Upward Farms. “RAZR’s modular nature allows us to tailor the lights to our system while increasing efficiency and reducing grow time.”
For more information about the RAZR Modular System and Fluence’s extended portfolio of LED solutions, visit www.fluence.science .
About Fluence by OSRAM
Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM , creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit https://fluence.science .
About Upward Farms
Upward Farms is a USDA-Certified Organic aquaponic vertical farm located in Brooklyn, NY. Upward Farms uses a breakthrough approach that marries modern vertical farming with the ancient practice of aquaponics. This method utilizes fish to fertilize crops in a complete ecosystem that relies on the naturally occurring microbiome, which is the superpower that has sustained life for millions of years. Upward Farms is dedicated to healing the broken food system & reconnecting eaters with flavorful, nutritious, local food. To learn more about Upward Farms, visit www.eatupwardfarms.com .
About Ecopromt
Ecopromt is a family-owned business that works in the horticulture sector, specialized in fresh herbs but also focuses on research and development on other crops. Ecopromt offers consultation on growing and technical advice, with a business strategy of combining biology, chemistry and automation so that growers around the world can get more effective with their crops. Ecopromt with its main office in Sweden is an official reseller of Fluence by OSRAM lights and manufacturer of our own integrated cart systems. Ecopromt also have a branch office in Harrisonburg, Virginia where we offer similar services.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210615005453/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom